Sibutramine is indicated for:
**Core Concept**
Sibutramine is a centrally acting, serotonin-norepinephrine reuptake inhibitor (SNRI) that was used as an adjunct in the treatment of obesity. It works by increasing the levels of norepinephrine and serotonin in the brain, which helps to reduce appetite and increase feelings of fullness.
**Why the Correct Answer is Right**
Sibutramine was indicated for the management of obesity, including weight loss and maintenance, in conjunction with a reduced-calorie diet. It was specifically approved for use in adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who have at least one weight-related condition such as hypertension, diabetes, or dyslipidemia. The mechanism of action involves the inhibition of norepinephrine and serotonin reuptake, which increases the levels of these neurotransmitters in the synaptic cleft and enhances satiety and weight loss.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because sibutramine is not primarily used for the treatment of depression. While it does affect the levels of neurotransmitters involved in mood regulation, its primary indication is for obesity management.
**Option B:** This option is incorrect because sibutramine is not a direct-acting anticholinergic agent. It does not directly affect the parasympathetic nervous system or cause anticholinergic side effects.
**Option C:** This option is incorrect because sibutramine is not a direct-acting vasodilator. It does not directly relax smooth muscle or cause vasodilation, but rather affects weight loss through its central mechanism of action.
**Clinical Pearl / High-Yield Fact**
It's essential to note that sibutramine was withdrawn from the market in several countries, including the US, due to concerns about its cardiovascular safety. This highlights the importance of monitoring the safety profile of medications and being aware of any changes in their regulatory status.
**Correct Answer: D. Management of obesity.**